|
1
|
Khan SA, Toledano MB and Taylor-Robinson
SD: Epidemiology, risk factors, and pathogenesis of
cholangiocarcinoma. HPB (Oxford). 10:77–82. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Seol MA, Chu IS, Lee MJ, Yu GR, Cui XD,
Cho BH, Ahn EK, Leem SH, Kim IH and Kim DG: Genome-wide expression
patterns associated with oncogenesis and sarcomatous
transdifferentation of cholangiocarcinoma. BMC Cancer. 11:782011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gruenberger B, Schueller J, Heubrandtner
U, Wrba F, Tamandl D, Kaczirek K, Roka R, Freimann-Pircher S and
Gruenberger T: Cetuximab, gemcitabine, and oxaliplatin in patients
with unresectable advanced or metastatic biliary tract cancer: a
phase 2 study. Lancet Oncol. 11:1142–1148. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Xu L, Hausmann M, Dietmaier W, Kellermeier
S, Pesch T, Stieber-Gunckel M, Lippert E, Klebl F and Rogler G:
Expression of growth factor receptors and targeting of EGFR in
cholangiocarcinoma cell lines. BMC Cancer. 10:3022010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
White DL, Radich J, Soverini S, Saunders
VA, Frede AK, Dang P, Cilloni D, Lin P, Mongay L, Woodman R, Manley
P, Slader C, Kim DW, Pane F, Martinelli G, Saglio G and Hughes TP:
Chronic phase chronic myeloid leukemia patients with low OCT-1
activity randomized to high-dose imatinib achieve better responses
and have lower failure rates than those randomized to standard-dose
imatinib. Haematologica. 97:907–914. 2012. View Article : Google Scholar
|
|
6
|
Zhang S, Lovejoy KS, Shima JE, Lagpacan
LL, Shu Y, Lapuk A, Chen Y, Komori T, Gray JW, Chen X, Lippard SJ
and Giacomini KM: Organic cation transporters are determinants of
oxaliplatin cytotoxicity. Cancer Res. 66:8847–8857. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jonker JW, Wagenaar E, Van Eijl S and
Schinkel AH: Deficiency in the organic cation transporters 1 and 2
(Oct1/Oct2 [Slc22a1/Slc22a2]) in mice abolishes renal secretion of
organic cations. Mol Cell Biol. 23:7902–7908. 2003.PubMed/NCBI
|
|
8
|
Zwart R, Verhaagh S, Buitelaar M,
Popp-Snijders C and Barlow DP: Impaired activity of the
extraneuronal monoamine transporter system known as uptake-2 in
Orct3/Slc22a3-deficient mice. Mol Cell Biol. 21:4188–4196. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Heise M, Lautem A, Knapstein J,
Schattenberg JM, Hoppe-Lotichius M, Foltys D, Weiler N, Zimmermann
A, Schad A, Gründemann D, Otto G, Galle PR, Schuchmann M and
Zimmermann T: Downregulation of organic cation transporters OCT1
(SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and
their prognostic significance. BMC Cancer. 12:1092012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chang Q, Chen J, Beezhold KJ, Castranova
V, Shi X and Chen F: JNK1 activation predicts the prognostic
outcome of the human hepatocellular carcinoma. Mol Cancer.
8:642009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Okabe H, Satoh S, Kato T, Kitahara O,
Yanagawa R, Yamaoka Y, Tsunoda T, Furukawa Y and Nakamura Y:
Genome-wide analysis of gene expression in human hepatocellular
carcinomas using cDNA microarray: identification of genes involved
in viral carcinogenesis and tumor progression. Cancer Res.
61:2129–2137. 2001.
|
|
12
|
Park T, Yi SG, Shin YK and Lee S:
Combining multiple microarrays in the presence of controlling
variables. Bioinformatics. 22:1682–1689. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Verhaagh S, Schweifer N, Barlow DP and
Zwart R: Cloning of the mouse and human solute carrier 22a3
(Slc22a3/SLC22A3) identifies a conserved cluster of three organic
cation transporters on mouse chromosome 17 and human 6q26-q27.
Genomics. 55:209–218. 1999. View Article : Google Scholar
|
|
14
|
Zwart R, Sleutels F, Wutz A, Schinkel AH
and Barlow DP: Bidirectional action of the Igf2r imprint control
element on upstream and downstream imprinted genes. Genes Dev.
15:2361–2366. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Schaeffeler E, Hellerbrand C, Nies AT,
Winter S, Kruck S, Hofmann U, van der Kuip H, Zanger UM, Koepsell H
and Schwab M: DNA methylation is associated with downregulation of
the organic cation transporter OCT1 (SLC22A1) in human
hepatocellular carcinoma. Genome Med. 3:822011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kitada N, Takara K, Minegaki T, Itoh C,
Tsujimoto M, Sakaeda T and Yokoyama T: Factors affecting
sensitivity to antitumor platinum derivatives of human colorectal
tumor cell lines. Cancer Chemother Pharmacol. 62:577–584. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yokoo S, Masuda S, Yonezawa A, Terada T,
Katsura T and Inui K: Significance of organic cation transporter 3
(SLC22A3) expression for the cytotoxic effect of oxaliplatin in
colorectal cancer. Drug Metab Dispos. 36:2299–2306. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Eckel F and Schmid RM: Chemotherapy in
advanced biliary tract carcinoma: a pooled analysis of clinical
trials. Br J Cancer. 96:896–902. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Valle J, Wasan H, Palmer DH, Cunningham D,
Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira
SP, Roughton M and Bridgewater J: Cisplatin plus gemcitabine versus
gemcitabine for biliary tract cancer. N Engl J Med. 362:1273–1281.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kerb R, Brinkmann U, Chatskaia N, Gorbunov
D, Gorboulev V, Mornhinweg E, Keil A, Eichelbaum M and Koepsell H:
Identification of genetic variations of the human organic cation
transporter hOCT1 and their functional consequences.
Pharmacogenetics. 12:591–595. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sakata T, Anzai N, Shin HJ, Noshiro R,
Hirata T, Yokoyama H, Kanai Y and Endou H: Novel single nucleotide
polymorphisms of organic cation transporter 1 (SLC22A1) affecting
transport functions. Biochem Biophys Res Commun. 313:789–793. 2004.
View Article : Google Scholar
|
|
22
|
Chen L, Pawlikowski B, Schlessinger A,
More SS, Stryke D, Johns SJ, Portman MA, Chen E, Ferrin TE, Sali A
and Giacomini KM: Role of organic cation transporter 3 (SLC22A3)
and its missense variants in the pharmacologic action of metformin.
Pharmacogenet Genomics. 20:687–699. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lazar A, Gründemann D, Berkels R, Taubert
D, Zimmermann T and Schömig E: Genetic variability of the
extraneuronal monoamine transporter EMT (SLC22A3). J Hum Genet.
48:226–230. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sakata T, Anzai N, Kimura T, Miura D,
Fukutomi T, Takeda M, Sakurai H and Endou H: Functional analysis of
human organic cation transporter OCT3 (SLC22A3) polymorphisms. J
Pharmacol Sci. 113:263–266. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shu Y, Sheardown SA, Brown C, Owen RP,
Zhang S, Castro RA, Ianculescu AG, Yue L, Lo JC, Burchard EG, Brett
CM and Giacomini KM: Effect of genetic variation in the organic
cation transporter 1 (OCT1) on metformin action. J Clin Invest.
117:1422–1431. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Song IS, Shin HJ and Shin JG: Genetic
variants of organic cation transporter 2 (OCT2) significantly
reduce metformin uptake in oocytes. Xenobiotica. 38:1252–1262.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cui R, Okada Y, Jang SG, Ku JL, Park JG,
Kamatani Y, Hosono N, Tsunoda T, Kumar V, Tanikawa C, Kamatani N,
Yamada R, Kubo M, Nakamura Y and Matsuda K: Common variant in
6q26-q27 is associated with distal colon cancer in an Asian
population. Gut. 60:799–805. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Eeles RA, Kote-Jarai Z, Giles GG, Olama
AA, Guy M, Jugurnauth SK, Mulholland S, Leongamornlert DA, Edwards
SM, Morrison J, Field HI, Southey MC, Severi G, Donovan JL, Hamdy
FC, Dearnaley DP, Muir KR, Smith C, Bagnato M, Ardern-Jones AT,
Hall AL, O’Brien LT, Gehr-Swain BN, Wilkinson RA, Cox A, Lewis S,
Brown PM, Jhavar SG, Tymrakiewicz M, Lophatananon A, Bryant SL; UK
Genetic Prostate Cancer Study Collaborators; British Association of
Urological Surgeons' Section of Oncology; UK ProtecT Study
Collaborators; Horwich A, Huddart RA, Khoo VS, Parker CC, Woodhouse
CJ, Thompson A, Christmas T, Ogden C, Fisher C, Jamieson C, Cooper
CS, English DR, Hopper JL, Neal DE and Easton DF: Multiple newly
identified loci associated with prostate cancer susceptibility. Nat
Genet. 40:316–321. 2008. View
Article : Google Scholar : PubMed/NCBI
|
